Patient characteristics (total 281 included, 9 patients excluded later)
| . | n (%) . | n (%) . | Total . |
|---|---|---|---|
| . | FC (139) . | FCA (133) . | 272 . |
| Male sex | 103 (74) | 100 (75) | 203 |
| Age <65 y | 105 (76) | 98 (74) | 203 |
| Age >65 y | 34 (24) | 35 (26) | 69 |
| WHO perf. status 0 | 89 (64) | 78 (59) | 167 |
| WHO perf. status 1 | 46 (33) | 49 (37) | 95 |
| WHO perf. status 2 | 3 (2) | 4 (3) | 7 |
| Stage A | 17 (12) | 13 (10) | 30 |
| Stage B | 74 (53) | 75 (56) | 149 |
| Stage C | 48 (35) | 45 (34) | 93 |
| 17p deletion | 18 (13) | 14 (11) | 32 |
| 11q deletion | 38 (27) | 30 (23) | 68 |
| Trisomy 12 | 23 (17) | 34 (26) | 57 |
| 13q deletion | 24 (9) | 24 (18) | 48 |
| No FISH aberrations | 29 (21) | 18 (14) | 47 |
| Missing FISH results regarding | |||
| Del17p | 1 (1) | 1 (1) | 2 |
| Del11q | — | 1 (1) | 1 |
| +12 | 14 (10) | 18 (14) | 32 |
| Unmutated IGHV | 113 (81) | 104 (78) | 217 |
| IGHV status not done | 17 (13) | 6 (5) | 23 |
| Β2-microglobulin >3.5 mg/L | 62 (45) | 62 (47) | 124 |
| Β2-microglobulin not done | 29 (21) | 22 (17) | 51 |
| . | n (%) . | n (%) . | Total . |
|---|---|---|---|
| . | FC (139) . | FCA (133) . | 272 . |
| Male sex | 103 (74) | 100 (75) | 203 |
| Age <65 y | 105 (76) | 98 (74) | 203 |
| Age >65 y | 34 (24) | 35 (26) | 69 |
| WHO perf. status 0 | 89 (64) | 78 (59) | 167 |
| WHO perf. status 1 | 46 (33) | 49 (37) | 95 |
| WHO perf. status 2 | 3 (2) | 4 (3) | 7 |
| Stage A | 17 (12) | 13 (10) | 30 |
| Stage B | 74 (53) | 75 (56) | 149 |
| Stage C | 48 (35) | 45 (34) | 93 |
| 17p deletion | 18 (13) | 14 (11) | 32 |
| 11q deletion | 38 (27) | 30 (23) | 68 |
| Trisomy 12 | 23 (17) | 34 (26) | 57 |
| 13q deletion | 24 (9) | 24 (18) | 48 |
| No FISH aberrations | 29 (21) | 18 (14) | 47 |
| Missing FISH results regarding | |||
| Del17p | 1 (1) | 1 (1) | 2 |
| Del11q | — | 1 (1) | 1 |
| +12 | 14 (10) | 18 (14) | 32 |
| Unmutated IGHV | 113 (81) | 104 (78) | 217 |
| IGHV status not done | 17 (13) | 6 (5) | 23 |
| Β2-microglobulin >3.5 mg/L | 62 (45) | 62 (47) | 124 |
| Β2-microglobulin not done | 29 (21) | 22 (17) | 51 |
FC, fludarabine and cyclophosphamide; PR, Partial remission; WHO perf., World Health Organization performance.